IQV Looks Smarter Buy Than Danaher Stock
IQV is Danaher’s peer in Life Sciences Tools & Services industry that has:
1) Lower valuation (P/OpInc) compared to Danaher stock
2) But higher revenue and operating income growth
This disconnect between valuation and performance could mean that you are better off buying IQV stock vs. DHR stock
Key Metrics Compared
- Netflix Stock Hits Key Support – Buying Opportunity?
- Intuit Stock Pulls Back to Support – Smart Entry?
- Steel Dynamics Earnings: Record Shipments And Margin Expansion Drive A Strong Quarter
- Robinhood Stock: The Multiple Tells The Wrong Story
- How ISRG Just Secured The U.S. Market
- How UNH Stock Is Trading Short-Term Margins For Long-Term Moats
| Metric | DHR | IQV |
|---|---|---|
| P/OpInc* | 27.4x | 13.0x |
| LTM OpInc Growth | -1.3% | 0.8% |
| 3Y Avg OpInc Growth | -10.7% | 7.9% |
| LTM Revenue Growth | 4.0% | 5.9% |
| 3Y Avg Revenue Growth | -0.1% | 4.2% |
OpInc = Operating Income, P/OpInc = Price To Operating Income Ratio
But do these numbers tell the full story? Read Buy or Sell DHR Stock to see if Danaher still has an edge that holds up under the hood. As a quick background, Danaher (DHR) provides professional, medical, industrial, and commercial products across Life Sciences, Diagnostics, and Environmental solutions, including lab automation, diagnostics systems, genomics, and microscopy technologies.
This is just one approach to evaluate investments. Trefis High Quality Portfolio evaluates much more, and is designed to reduce stock-specific risk while giving upside exposure
Is The Mismatch In Stock Price Temporary
One way to check if Danaher stock is expensive now versus the other tickers would be to see how these metrics compared across companies exactly a year ago. Specifically, if there has been a marked reversal in the trend for Danaher in the last 12 months, then there is a chance that the current mismatch is likely to reverse. On the other hand, a persistent underperformance in revenue and operating income growth for Danaher would reinforce the conclusion that the stock is expensive compared to its peers, but may not revert soon
Key Metrics Compared 1 Yr Prior
| Metric | DHR | IQV |
|---|---|---|
| P/OpInc* | 28.8x | 10.8x |
| LTM OpInc Growth | -3.6% | 4.3% |
| 3Y Avg OpInc Growth | -13.7% | 6.0% |
| LTM Revenue Growth | 2.9% | 3.8% |
| 3Y Avg Revenue Growth | -2.5% | 3.6% |
OpInc = Operating Income
Additional Metrics To Consider
| Metric | DHR | IQV |
|---|---|---|
| P/S | 5.3x | 1.8x |
| Market Cap (Current) | $ 130.3 Bil | $ 29.8 Bil |
| LTM Revenue | $ 24.78 Bil | $ 16.31 Bil |
| LTM Opinc | $ 4.76 Bil | $ 2.29 Bil |
| LTM Op Margin | 19.2% | 14.0% |
OpInc = Operating Income
Alternate buying based on valuation, while attractive, needs to be evaluated carefully from multiple angles. Such multi-factor analysis is exactly how we construct Trefis portfolio strategies. If you want upside with a smoother ride than an individual stock, consider the High Quality portfolio, which has outperformed its benchmark – a combination of the S&P 500, Russell, and S&P midcap index.